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a b s t r a c t
Background: Beta-blockers are frequently used in patients with mitral stenosis to control the
heart rate and alleviate exercise-related symptoms. The objective of our study was to
examine whether ivabradine was superior to atenolol for achieving higher exercise capacity
in patients with moderate mitral stenosis in sinus rhythm. We also evaluated their effects on
left ventricular myocardial performance index (MPI).
Methods and results: Eighty-two patients with moderate mitral stenosis in sinus rhythm were
randomized to receive ivabradine (n = 42) 5 mg twice daily or atenolol (n = 40) 50 mg daily for
6 weeks. Transthoracic echocardiography and treadmill test were performed at baseline and
after completion of 6 weeks of treatment. Mean total exercise duration in seconds markedly
improved in both study groups at 6 weeks (298.57  99.05 s vs. 349.12  103.53 s; p = 0.0001 in
ivabradine group, 290.90  92.42 s vs. 339.90  99.84 s; p = 0.0001 in atenolol group). On head-
to-head comparison, there was no signiﬁcant change in improvement of exercise time
between ivabradine and atenolol group (p = 0.847). Left ventricular MPI did not show any
signiﬁcant change from baseline and at 6 weeks in both drug groups (49.8%  8% vs. 48.3%
 7% in ivabradine group, 52.9%  10% vs. 50.9%  10% in atenolol groups; p = 0.602).
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Fig. 1 – Trial protocol-flow chart.
Conclusion: Ivabradine or atenolol can be used for heart rate control in patients with
moderate mitral stenosis in sinus rhythm. Ivabradine is not superior to atenolol for control-
ling heart rate or exercise capacity. Left ventricular MPI was unaffected by either of the drugs.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
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Rheumatic mitral stenosis is the commonest valvular heart
disease in developing countries.1 Beta-blockers or calcium
channel blockers are used in patients with mitral stenosis for
heart rate control.2 These drugs act by reducing exercise-
induced rise in heart rate and cardiac output and thereby
decreasing pulmonary venous pressure and improving effort-
related symptoms.3,4 Results from various clinical and
hemodynamic studies with beta-blocker have been conﬂict-
ing.3,5–12 Studies with tissue Doppler imaging have shown left
ventricular dysfunction in patients with isolated rheumatic
mitral stenosis.13,14 These studies did not discuss negative
chronotropic agents, the use of which may also have
contributed for higher prevalence of ventricular dysfunction.
Ivabradine is a pure heart rate lowering drug that acts by
inhibiting the If current, an important ionic current that
determines the pacemaker activity of sinus node. It has
selective action on the sinus node and is thus devoid of the
usual side effects of beta-blockers.15 Ivabradine seems as an
attractive option for heart rate reduction in patients with
mitral stenosis in sinus rhythm. One recent study has shown
that patients with rheumatic mitral stenosis on ivabradine
have higher total exercise duration and a lower peak heart rate
during exercise than patients on atenolol.16 The present study
was undertaken to evaluate the effects of ivabradine on
exercise capacity and left ventricular function in patients with
moderate mitral stenosis in sinus rhythm.
2. Methods
This study was designed as a randomized, open-label, parallel
group trial of ivabradine and atenolol in patients with
moderate mitral stenosis in sinus rhythm. The study was
approved by institutional ethics committee. A written in-
formed consent was obtained from patients included in the
study. The trial was registered at http://ctri.nic.in (identiﬁer:
CTRI/2012/10/003076). The study period was from November
2012 to February 2014.
3. Protocol
We included consecutive patients (age between 18 and 60
years) with moderate mitral stenosis (2-D mitral valve area 1–
1.5 cm2) in sinus rhythm in NYHA functional class I–II. Patients
were excluded if they had other signiﬁcant valvular lesions,
NYHA functional class III–IV, inability to perform treadmill test
(TMT)/contraindication for TMT, urgent need for surgical
treatment or balloon mitral valvotomy, pregnancy, known
allergy/intolerance to study drugs, known coronary arterydisease, or left ventricular ejection fraction (EF) less than 50%.
For those patients who were on heart rate reducing medica-
tion, the drug was discontinued for a period of ﬁve half-lives.
Baseline transthoracic echocardiography and TMT were
performed. The patients were randomized according to
computer-generated random number sequence. Participants
randomized to ivabradine arm received 5 mg twice daily and
those randomized to atenolol arm received 50 mg once daily
for a period of 6 weeks. Echocardiography and TMT were
repeated at 6 weeks. Primary outcome was change in total
duration of exercise from baseline TMT and at 6 weeks.
Secondary outcome was change in the LV myocardial
performance index (MPI) by tissue Doppler imaging. The trial
protocol is depicted in Fig. 1.
Detailed clinical evaluation of all study subjects was done.
Transthoracic echocardiography was done to assess mitral
valve area, mean gradient across the mitral valve, left atrial
size, tricuspid regurgitation, pulmonary artery pressure, and
EF as per recommendations of the American Society of
Echocardiography.17 Bruce TMT protocol was used to assess
heart rate response, exercise duration, and peak heart rate
achieved. Operators who were blinded to the treatment arm
performed TMT. Exercise was terminated on development of
symptoms or attainment of more than 10 metabolic equiva-
lents.
Tissue Doppler indices like isovolumic contraction time
(ICT), isovolumic relaxation time (IRT), and ejection time (ET)
were measured for obtaining MPI at septal and lateral mitral
annulus in apical 4-chamber view and at anterior, posterior
mitral annulus in apical 2-chamber view, respectively.
Consecutive 3 values were taken for calculation of mean of
each parameter. MPI was calculated using the formula, MPI =
(ICT + IRT)/ET.
Table 1 – Baseline characteristics of patients.
Atenolol (n = 40) Ivabradine (n = 42) p value
Male n (%) 4 (10%) 4 (9.5%) 0.942
Female n (%) 36 (90%) 38 (90.5%) 0.942
Age in years (SD) 38.92 (9.417) 37.19 (10.435) 0.433
Mean duration of symptoms – years 6.54 (3.492) 5.46 (3.081) 0.433
Baseline pulse rate 75.55 (5.074) 75.45 (6.808) 0.942
Systolic BP – mmHg 111.50 (12.38) 113.95 (8.88) 0.304
Diastolic BP – mmHg 71.55 (8.057) 70.57 7.893 0.580
LV-EDD mm 44.25 (5.448) 44.02 (4.931) 0.844
LV-ESD mm 29.15 (4.123) 27.79 (6.178) 0.245
LV EF % 65.63 (6.655) 64.79 (6.039) 0.551
MVA (cm2) 1.284 (0.0915) 1.287(0.0878) 0.856
MV mean gradient – mmHg 9.07 (2.505) 9.33 (2.773) 0.660
SMV cm/s 6.8 (2.7) 6.3(0.6) 0.274
MPI % 52 (10) 49 (7) 0.337
TMT – exercise time – S 290 (92) 298 (99) 0.718
Maximum HR at TMT 152.95 (14.03) 154.8 (11.05) 0.490
Values are mean (SD) unless otherwise indicated. LV-EDD – left ventricular end-diastolic diameter, LV-ESD – left ventricular end-systolic
diameter, LV EF – left ventricle ejection fraction, SD – standard deviation, MVA – mitral valve area, SMV – systolic myocardial velocity, MPI –
myocardial performance index, TMT – treadmill test, HR – heart rate.
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Statistical analysis was performed using statistical package for
social science software (SPSS Inc. Chicago, Illinois, version
18.0). Continuous variables were given as mean  SD, and
categorical variables were given as percentages. The estimated
sample size was 80.
5. Results
Baseline characteristics of the patients are given in Table 1. A
total of 82 patients (n = 42 in ivabradine group, n = 40 in
atenolol group), including 8 males (9.8%) and 74 females
(90.2%) were studied. The mean age of the study population in
ivabradine group was 37.2 years, SD: 10.44 years, and in
atenolol group it was 38.92 years, SD: 9.42 years. Baseline
characteristics of both study groups were comparable. Mean
total exercise duration in seconds markedly improved in both
study groups after 6 weeks of drug treatment (298.57 s, SD: 9.05
vs. 349.12 s SD: 103.53; p = 0.0001 in ivabradine group, 290.90 s,
SD: 92.42 vs. 339.9 s, SD  99.84; p = 0.0001 in atenolol group)
(Table 2). There was also signiﬁcant change in maximum heart
rate achieved at 6 weeks TMT compared to baseline in both
study groups (154.88, SD: 11.052 bpm vs. 162.52, SD: 9.91 bpm;
p = 0.0001 in ivabradine group, 152.95, SD: 14.03 bpm vs. 162.5,Table 2 – Effect of atenolol and ivabradine on primary outcome
Exercise duration – s (baseline) 
Atenolol (SD) (n = 40) 290 (92.42) 
Ivabradine (SD) (n = 42) 298.5 (99.05) 
Paired difference in exercise
duration – s (mean)
Atenolol (n = 40) 49 
Ivabradine (n = 42) 50.54 SD: 10.48 bpm; p = 0.0001 in atenolol group). On head-to-head
comparison (Table 2, Fig. 2), there was no signiﬁcant change in
improvement of exercise time between ivabradine and
atenolol group (p = 0.847). Left ventricular MPI did not show
signiﬁcant change between baseline and at 6 weeks (Table 3,
Fig. 3) in both drug groups (49.8%, SD: 8% vs. 48.3%, SD: 7% in
ivabradine group, 52.9% SD: 10% vs. 50.95, SD: 10% in atenolol
group; p = 0.602).
6. Discussion
The role of beta-blocker for rate control in mitral stenosis has
been evaluated in various studies, but the use of ivabradine as
heart rate controlling medication in mitral stenosis has not
been validated. Hemodynamic studies with beta-blockers in
mitral stenosis, performed under conditions of rest and
exercise, have demonstrated reduction in pulmonary capillary
wedge pressure, but the effect of beta-blockade on cardiac
output has been unpredictable.8,18–21 Mardikar et al.22 showed
signiﬁcant improvement in exercise time with atenolol
(100 mg once daily), whereas in a study by Stoll et al.,4 there
was no beneﬁt of atenolol in doses of either 50 mg or 100 mg
once daily. Patients having poor baseline effort tolerance
showed beneﬁcial effect with use of beta-blockers whereas no
further beneﬁt was observed in those with good baseline effort – exercise performance.
Exercise duration – s (at 6 weeks) p value
339 (99.84) 0.0001
349 (103.5) 0.0001
Paired difference in exercise




Fig. 2 – Effect of atenolol and ivabradine on primary outcome
– exercise performance.
Fig. 3 – Effect of atenolol and ivabradine on myocardial
performance index.
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beneﬁt of various beta-blockers (atenolol, propranolol, and
acebutolol) in patients with MS and sinus rhythm.
In the present study, ivabradine is found to be equally
effective as beta-blocker in improving the exercise capacity. A
signiﬁcant improvement in the exercise capacity was found to
be independent of medication used. The mean total duration
of exercise and maximum heart rate achieved during TMT at 6
weeks of drug therapy was comparable between both drug
arms. Pasceri et al.24 demonstrated that administration of
ivabradine resulted in lower heart rate, and reduction of
transmitral gradients in patients with mitral stenosis in sinus
rhythm. Parakh et al.16 reported that ivabradine (5 mg twice
daily) was superior to atenolol (50 mg once daily) for achieving
greater exercise capacity and control of heart rate in patients
with mild to moderate MS in sinus rhythm. Contrary to this
study, there was no signiﬁcant difference in improvement of
exercise capacity among the heart rate reducing medications
used in our study.
In approximately one-fourth of patients with pure mitral
stenosis, there is a decrease in left ventricular systolic
performance.25,26 Even in the presence of preserved global
left ventricular function as measured by ejection fraction,
some patients may exhibit impairment in long-axis function
as shown by tissue Doppler echo.27 There are no previous
studies evaluating the effect of ivabradine vis-a-vis atenolol onTable 3 – Effect of atenolol and ivabradine on myocardial perfo
MPI (%) (baseline) 
Atenolol (SD) (n = 40) 52.93 (10.11) 
Ivabradine (SD) (n = 42) 49.86 (7.9) 
Difference in MPI (Mean) 
Atenolol (n = 40) 1.96% 
Ivabradine (n = 42) 1.54% 
MPI – myocardial performance index.left ventricular MPI in patients with mitral stenosis in sinus
rhythm. In the present study no signiﬁcant difference was
observed in left ventricular MPI between atenolol and
ivabradine.
In this trial, we selected only moderate mitral stenosis
patients with symptoms. Symptomatic severe mitral stenosis
was excluded due to concerns of worsening during the six-
week waiting period. We used ﬁxed low doses of both study
drugs, because majority of the patients had low body mass
index. Our study has shown that ivabradine can be used as an
alternative therapy for heart rate reduction in patients with
moderate mitral stenosis in sinus rhythm in patients intoler-
ant to beta-blocker therapy. Whether it can be used as add-on
therapy with beta-blocker for optimal heart rate reduction in
mitral stenosis with sinus rhythm needs further validation. In
developing countries, high cost of this drug may limit its
routine use in this subset of patients.
7. Study limitation
Parallel group design was the major limitation of our study. A
cross-over study design with a washout period in between
could have provided better comparative data regarding effects
of study drugs on exercise capacity and MPI. Both drugs were
used in ﬁxed submaximal doses, and no effort was made to uprmance index.
MPI (%) (6 weeks) p value
50.97 (10.72) 0.130
48.3 (6.92) 0.186
Standard deviation p value
3.993 0.602
3.271
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is also subject to the inherent bias of an open-label design.
Noninferiority of ivabradine could not be proven in this study
due to insufﬁcient sample size.
8. Conclusion
Atenolol or ivabradine can be used for heart rate control in
moderate mitral stenosis patients in sinus rhythm. Both drugs
signiﬁcantly improve exercise capacity in terms of total
exercise duration. Ivabradine is not superior to atenolol for
controlling heart rate in moderate mitral stenosis. Left
ventricular MPI was unaffected by both drugs during the
period of study. Ivabradine can be used as an alternative
therapy for heart rate control in patients with moderate mitral
stenosis in sinus rhythm who are intolerant to beta-blockers.
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